PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 2160723
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 2160723
According to Stratistics MRC, the Global Laboratory Automation & High-Throughput Screening Market is accounted for $34.8 billion in 2026 and is expected to reach $68.9 billion by 2034 growing at a CAGR of 8.9% during the forecast period. Laboratory Automation & High-Throughput Screening combines robotics, automated equipment, software platforms, and analytical technologies to enhance the efficiency and accuracy of laboratory operations. These solutions automate activities such as sample preparation, liquid handling, assay execution, data acquisition, and result analysis. High-throughput screening allows researchers to examine extensive libraries of compounds, samples, and experimental variables within shorter periods. By minimizing manual tasks, these technologies improve workflow consistency, reproducibility, processing capacity, and operational efficiency while accelerating research activities and discovery processes in pharmaceutical, biotechnology, clinical, and academic laboratory settings.
According to NIH's National Center for Advancing Translational Sciences (NCATS), its automated primary screening system has storage capacity for more than 3 million compound wells and approximately 1.5 million assay wells, with multiple assays capable of running in parallel.
Increasing demand for laboratory efficiency and productivity
Rising emphasis on laboratory efficiency and productivity is supporting market expansion as organizations seek faster and more reliable workflows. Automation technologies can handle repetitive laboratory activities, reduce human intervention, and maintain consistent processing standards. Pharmaceutical and biotechnology organizations increasingly use these capabilities to shorten experimental timelines and standardize operations. As laboratories prioritize productivity, operational optimization, and reduced processing delays, adoption of automated and high-throughput screening solutions continues to increase across research and testing environments.
High initial investment and implementation costs
Significant upfront expenses associated with laboratory automation can limit market adoption, particularly among organizations operating with restricted budgets. Robotic equipment, automated analyzers, software, infrastructure, and system integration may require considerable financial investment. Additional spending on installation, validation, maintenance, technology upgrades, and workforce training can increase the overall cost of implementation. Furthermore, integrating new automated platforms with established laboratory processes can involve technical complexity, additional resources, and longer implementation periods, potentially slowing the transition toward automated and high-throughput laboratory operations.
Expansion of automation in emerging markets
Growing adoption of laboratory automation in developing economies offers considerable expansion potential for the market. Increasing pharmaceutical, biotechnology, diagnostic, and academic research activities are encouraging laboratories to improve operational efficiency through automated technologies. Improvements in healthcare infrastructure and investments in research and biotechnology facilities can further accelerate technology adoption. As laboratories modernize across emerging economies, technology providers have opportunities to offer scalable and economical automation solutions that address rising requirements for efficient testing, screening, and research operations.
Data security and system vulnerability risks
Cybersecurity concerns can threaten the adoption of connected laboratory automation and high-throughput screening systems. Modern laboratories increasingly use networked instruments, digital platforms, cloud technologies, and centralized data environments, which can create vulnerabilities to unauthorized access and cyber incidents. Security breaches may expose confidential research information, intellectual property, experimental findings, and operational data. Consequently, organizations may need stronger security infrastructure, monitoring, and protection measures, adding costs and technical complexity that could slow adoption of increasingly interconnected laboratory automation solutions.
The COVID-19 pandemic accelerated demand for laboratory automation and high-throughput screening as laboratories needed faster testing, greater processing capacity, and reduced dependence on manual procedures. Pharmaceutical and research organizations also increased screening efforts focused on vaccines, treatments, and diagnostic solutions. Equipment deliveries and installations were temporarily affected by supply-chain challenges and operational restrictions. However, the pandemic highlighted the benefits of automation and encouraged greater investment in scalable, efficient laboratory technologies for future research and testing needs.
The automated liquid handling systems segment is expected to be the largest during the forecast period
The automated liquid handling systems segment is expected to account for the largest market share during the forecast period because they support essential laboratory processes involving precise and reliable movement of liquids. By automating pipetting, dispensing, dilution, and sample preparation, these systems minimize repetitive manual work and improve consistency. Their usefulness across drug discovery, pharmaceutical development, biotechnology, genomics, and clinical testing contributes to broad utilization. Compatibility with robotic equipment and high-throughput screening platforms also strengthens their role in automated workflows.
The contract research organizations (CROs) segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the contract research organizations (CROs) segment is predicted to witness the highest growth rate, positioned for strong growth as pharmaceutical and biotechnology businesses increasingly rely on external providers for research and testing requirements. CROs need scalable technologies to handle extensive sample volumes, experimental workloads, and screening projects efficiently. Automation enables these organizations to increase processing capacity, minimize repetitive tasks, maintain standardized procedures, and shorten project timelines. Rising outsourcing of drug discovery, preclinical studies, analytical services, and specialized research activities is further encouraging CROs to adopt sophisticated laboratory automation and high-throughput screening technologies.
During the forecast period, the North America region is expected to hold the largest market share because of its mature pharmaceutical and biotechnology industries, advanced research capabilities, and widespread use of automated laboratory solutions. Numerous research organizations, clinical laboratories, and contract research organizations across the region depend on automation to improve laboratory processes. In addition, developed healthcare infrastructure and a strong presence of laboratory technology companies contribute to North America's leading position across automation and high-throughput screening applications.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as pharmaceutical, biotechnology, and research activities continue expanding. Increasing investments in drug development, clinical studies, genomics, and sophisticated diagnostic capabilities are creating stronger demand for laboratory automation. Improvements in healthcare infrastructure, greater use of advanced research technologies, and growing laboratory service outsourcing are further supporting adoption. Expanding biotechnology centers and strengthening research ecosystems across the region are encouraging laboratories to implement automated platforms that enhance efficiency, scalability, and high-throughput screening capabilities.
Key players in the market
Some of the key players in Laboratory Automation & High-Throughput Screening Market include Tecan Group Ltd., Hamilton Company, Beckman Coulter Life Sciences, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Revvity, Inc., F. Hoffmann-La Roche Ltd., Qiagen N.V., Eppendorf SE, SPT Labtech, Automata Technologies, Hudson Robotics, Inc., BMG LABTECH GmbH, Opentrons Labworks Inc., HighRes Biosolutions, Inc., Becton, Dickinson and Company and Aurora Biomed Inc.
In January 2026, BD (Becton, Dickinson and Company) and Ypsomed are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak(TM) XtraFlow(TM) Glass Prefillable Syringe. This innovation is designed to be fully compatible with Ypsomed's YpsoMate(R) 5.5 autoinjector platform, expanding options for pharmaceutical companies and patients who require large-volume subcutaneous self-injections.
In October 2025, Thermo Fisher Scientific Inc. has agreed to acquire Clario Holdings Inc., a provider of digital endpoint data solutions for clinical trials. The deal includes potential additional earnout and other payments contingent on future performance. Clario's platform integrates clinical trial endpoint data from devices, sites, and patients, enabling pharmaceutical and biotechnology companies to digitally collect, manage, and analyze clinical evidence across all phases of drug development.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.